Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02230670 · ClinicalTrials.gov registry record · Phase 2

A Study of IDN-6556 in Subjects With Liver Cirrhosis

A Phase 2 study of Liver Cirrhosis and Hepatic Cirrhosis, sponsored by Conatus Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
87
Enrollment target
20
Study locations

NCT02230670 is a Phase 2 study of Liver Cirrhosis and Hepatic Cirrhosis that has completed, run by Conatus Pharmaceuticals. The registered enrollment target is 87 participants, below the 999-participant average among 15 other Liver Cirrhosis trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02230670, a Phase 2 study of Liver Cirrhosis and Hepatic Cirrhosis, has completed, sponsored by Conatus Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
87 participants
Enrollment target
20
Study locations

Study Summary

This is a multicenter study to see if treatment with IDN-6556 can help improve the liver function of patients with liver cirrhosis with Model for End-Stage Liver Disease scores between 11-18.

Conditions Studied

Liver Cirrhosis Hepatic Cirrhosis

Interventions

  • DRUG Placebo
  • DRUG IDN-6556

Study Locations (20)

California

  • Scripps Clinic - La Jolla
  • Loma Linda University Medical Center - Loma Linda
  • Cedar-Sinai Medical Center - Los Angeles
  • Univeristy of California, San Diego - San Diego
  • California Pacific Medical Center - San Francisco

New York

  • North Shore University Hospital - Manhasset
  • NYU Medical Center - New York
  • Mt. Sinai School of Medicine - New York

Florida

  • University of Florida - Gainesville
  • University of Miami - Miami

Illinois

  • University of Chicago - Chicago
  • Loyola University Medical Cente - Maywood

Alabama

  • University of Alabama at Birmingham - Birmingham

Georgia

  • Piedmont Atlanta Hospital - Atlanta

Indiana

  • Indiana University - Indianapolis

Kentucky

  • University of Louisville - Louisville

Trial Details

FieldValue
Enrollment Target 87 participants
Start Date 2014-08
Est. Completion 2016-01
Phase Phase 2

Sponsor

Conatus Pharmaceuticals

16 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02230670

The ClinicalTrials.gov registry entry for NCT02230670 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 999-participant average among 15 other Liver Cirrhosis trials with a reported enrollment target (91% lower). The listed sponsor is Conatus Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Liver Cirrhosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02230670 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, New York, Florida.

Frequently Asked Questions

What is clinical trial NCT02230670 about?

NCT02230670 is a clinical study titled "A Study of IDN-6556 in Subjects With Liver Cirrhosis". This is a multicenter study to see if treatment with IDN-6556 can help improve the liver function of patients with liver cirrhosis with Model for End-Stage Liver Disease scores between 11-18.

What is the current status of trial NCT02230670?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2014-08. Estimated completion is 2016-01.

What conditions does trial NCT02230670 study?

This clinical trial studies the following conditions: Liver Cirrhosis, Hepatic Cirrhosis.

What interventions are being tested in trial NCT02230670?

The interventions under investigation include: Placebo (DRUG), IDN-6556 (DRUG).

Who is sponsoring clinical trial NCT02230670?

This trial is sponsored by Conatus Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02230670 being conducted?

This trial has 20 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Liver Cirrhosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Liver Cirrhosis

All registered trials for this condition

Hepatic Cirrhosis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.